Shinya Kobayashi
Research Subjects
Research Interests
Shinya Kobayashi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Yoshinobu Yamazaki
Pharmacology Research and Development, Kissei Pharmaceutical Co. Ltd., Nagano and Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan
7 shared publicationsYuji Hoyano
Pharmacology Research and Development, Kissei Pharmaceutical Co. Ltd., Nagano and Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan
5 shared publicationsHiroshi Kusama
3 shared publicationsKenjiro Kohri
Pharmacology Research and Development, Kissei Pharmaceutical Co. Ltd., Nagano and Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan
3 shared publicationsMamoru Kobayashi
Pharmacology Research and Development, Kissei Pharmaceutical Co. Ltd., Nagano 399-8304, Japan
3 shared publications- Satoshi Tatemichi
Pharmacology Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., Nagano, Japan
3 shared publications
Latest Publications
- 1 January 2010
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 183 (1) , 357-361
Effects of Silodosin and Naftopidil on the Distal Ureter and Cardiovascular System in Anesthetized Dogs: Comparison of Potential Medications for Distal Ureteral Stone Passage
Purpose: We compared the effects of the selective α1A-adrenoceptor antagonist silodosin and the selective α1D-adrenoceptor antagonist naftopidil on intraureteral pressure in anesthetized dogs and e...
- 1 January 2010
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 183 (1) , 357-361
Effects of Silodosin and Naftopidil on the Distal Ureter and Cardiovascular System in Anesthetized Dogs: Comparison of Potential Medications for Distal Ureteral Stone Passage
Purpose: We compared the effects of the selective α1A-adrenoceptor antagonist silodosin and the selective α1D-adrenoceptor antagonist naftopidil on intraureteral pressure in anesthetized dogs and e...
- 24 June 2009
- Published by Elsevier in European Journal of Pharmacology
- Vol. 613 (1-3) , 135-140
Effects of silodosin and tamsulosin on the urethra and cardiovascular system in young and old dogs with benign prostatic hyperplasia
- 24 June 2009
- Published by Elsevier in European Journal of Pharmacology
- Vol. 613 (1-3) , 135-140
Effects of silodosin and tamsulosin on the urethra and cardiovascular system in young and old dogs with benign prostatic hyperplasia
- 4 March 2009
- Published by Springer Nature in World Journal of Urology
- Vol. 27 (6) , 775-780
Gene expressions and mechanical functions of α1-adrenoceptor subtypes in mouse ureter
Purpose This study was performed to characterize the α1-adrenoceptor subtypes in mouse ureters as regards gene expressions and contractile functions. Methods The mRNAs for these subtypes were quantified by the real-time quantitative reverse transcription polymerase chain reaction. In a functional study, α1-adrenoceptor antagonists were evaluated against the noradrenaline-induced contraction in mouse isolated ureteral preparations. Results In mouse ureter, the relative mRNA expression levels for α1a-, α1b- and α1d-adrenoceptors were 74.5, 14.3 and 11.2%, respectively. Adrenaline and noradrenaline each produced a concentration-dependent phasic contraction (pD 2 values, 5.73 ± 0.05 and 5.69 ± 0.06, respectively). Prazosin (non-selective α1-adrenoceptor antagonist), silodosin (selective α1A-adrenoceptor antagonist), and BMY-7378 (selective α1D-adrenoceptor antagonist) all shifted the concentration–response curve for noradrenaline to the right, the rank order of potencies (apparent pA 2 values) being silodosin (9.32 ± 0.11) > prazosin (8.55 ± 0.10) > BMY-7378 (6.06 ± 0.15). The α1A-adrenoceptor antagonist silodosin was thus much more effective than the α1D-adrenoceptor antagonist BYM-7378. Conclusions Our results demonstrate that in mouse ureters: the mRNA for the α1A-adrenoceptor was more prevalent than those for the α1B- and α1D-adrenoceptors, and that among these subtypes, the α1A-adrenoceptor plays the major role in noradrenaline-induced contraction.
- 4 March 2009
- Published by Springer Nature in World Journal of Urology
- Vol. 27 (6) , 775-780
Gene expressions and mechanical functions of α1-adrenoceptor subtypes in mouse ureter
Purpose This study was performed to characterize the α1-adrenoceptor subtypes in mouse ureters as regards gene expressions and contractile functions. Methods The mRNAs for these subtypes were quantified by the real-time quantitative reverse transcription polymerase chain reaction. In a functional study, α1-adrenoceptor antagonists were evaluated against the noradrenaline-induced contraction in mouse isolated ureteral preparations. Results In mouse ureter, the relative mRNA expression levels for α1a-, α1b- and α1d-adrenoceptors were 74.5, 14.3 and 11.2%, respectively. Adrenaline and noradrenaline each produced a concentration-dependent phasic contraction (pD 2 values, 5.73 ± 0.05 and 5.69 ± 0.06, respectively). Prazosin (non-selective α1-adrenoceptor antagonist), silodosin (selective α1A-adrenoceptor antagonist), and BMY-7378 (selective α1D-adrenoceptor antagonist) all shifted the concentration–response curve for noradrenaline to the right, the rank order of potencies (apparent pA 2 values) being silodosin (9.32 ± 0.11) > prazosin (8.55 ± 0.10) > BMY-7378 (6.06 ± 0.15). The α1A-adrenoceptor antagonist silodosin was thus much more effective than the α1D-adrenoceptor antagonist BYM-7378. Conclusions Our results demonstrate that in mouse ureters: the mRNA for the α1A-adrenoceptor was more prevalent than those for the α1B- and α1D-adrenoceptors, and that among these subtypes, the α1A-adrenoceptor plays the major role in noradrenaline-induced contraction.
- Open Access
- 1 January 2009
- Published by Japan Society of Smooth Muscle Research in Journal of Smooth Muscle Research
- Vol. 45 (4) , 187-195
Effects of four different .ALPHA.1-adrenoceptor antagonists on .ALPHA.-adrenoceptor agonist-induced contractions in isolated mouse and hamster ureters
To compare the efficacy of the selective alpha(1A)-adrenoceptor antagonist silodosin with those of doxazosin, terazosin, and alfuzosin against alpha-adrenoceptor agonist-induced contractions in mouse and hamster ureters. The four alpha(1)-adrenoceptor antagonists were evaluated against norepinephrine-induced phasic contractions in mouse isolated ureteral preparations and against phenylephrine-induced sustained contractions in hamster isolated ureteral preparations using a functional experimental technique. In mouse ureters, silodosin (a selective alpha(1A)-adrenoceptor antagonist), doxazosin (a nonselective alpha(1)-adrenoceptor antagonist), terazosin (a nonselective alpha(1)-adrenoceptor antagonist), and alfuzosin (a nonselective alpha(1)-adrenoceptor antagonist) all shifted the norepinephrine concentration-response curve to the right. The rank order of potencies (pK(B) value) was silodosin (9.47 +/- 0.16) > doxazosin (8.62 +/- 0.15) > terazosin (8.39 +/- 0.16) > alfuzosin (8.03 +/- 0.12). In hamster ureters, all four antagonists shifted the phenylephrine concentration-response curve to the right, the rank order of potencies being silodosin (10.09 +/- 0.13) > doxazosin (8.22 +/- 0.16) > terazosin (7.75 +/- 0.15) > alfuzosin (7.70 +/- 0.10). In each case, silodosin was much more potent than the other three drugs. In this study, silodosin suppressed both mouse and hamster ureteral contractions more potently than doxazosin, terazosin, or alfuzosin. Hence, this alpha(1A)-adrenoceptor antagonist warrants further study as a potentially very useful medication for stone passage in urolithiasis patients.
- 1 January 2009
- Published by Japan Society of Smooth Muscle Research in Journal of Smooth Muscle Research
- Vol. 45 (4) , 187-195
Open AccessEffects of four different .ALPHA.1-adrenoceptor antagonists on .ALPHA.-adrenoceptor agonist-induced contractions in isolated mouse and hamster ureters
To compare the efficacy of the selective alpha(1A)-adrenoceptor antagonist silodosin with those of doxazosin, terazosin, and alfuzosin against alpha-adrenoceptor agonist-induced contractions in mouse and hamster ureters. The four alpha(1)-adrenoceptor antagonists were evaluated against norepinephrine-induced phasic contractions in mouse isolated ureteral preparations and against phenylephrine-induced sustained contractions in hamster isolated ureteral preparations using a functional experimental technique. In mouse ureters, silodosin (a selective alpha(1A)-adrenoceptor antagonist), doxazosin (a nonselective alpha(1)-adrenoceptor antagonist), terazosin (a nonselective alpha(1)-adrenoceptor antagonist), and alfuzosin (a nonselective alpha(1)-adrenoceptor antagonist) all shifted the norepinephrine concentration-response curve to the right. The rank order of potencies (pK(B) value) was silodosin (9.47 +/- 0.16) > doxazosin (8.62 +/- 0.15) > terazosin (8.39 +/- 0.16) > alfuzosin (8.03 +/- 0.12). In hamster ureters, all four antagonists shifted the phenylephrine concentration-response curve to the right, the rank order of potencies being silodosin (10.09 +/- 0.13) > doxazosin (8.22 +/- 0.16) > terazosin (7.75 +/- 0.15) > alfuzosin (7.70 +/- 0.10). In each case, silodosin was much more potent than the other three drugs. In this study, silodosin suppressed both mouse and hamster ureteral contractions more potently than doxazosin, terazosin, or alfuzosin. Hence, this alpha(1A)-adrenoceptor antagonist warrants further study as a potentially very useful medication for stone passage in urolithiasis patients.
- 1 March 2006
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 126 (Special) , 225-230
Effect of Silodosin on Intraurethral Pressure Increase Induced by Hypogastric Nerve Stimulation in Dogs with Benign Prostatic Hyperplasia
We compared the urethral and cardiovascular effects of silodosin (selective α_-adrenoceptor antagonist), a novel medication for benign prostatic hyperplasia (BPH), with those of tamsulosin (selective α_/α_-adrenoceptor antagonist) and naftopidil (selective α_-adrenoceptor antagonist). We evaluated the effects of these three drugs on the increase in intraurethral pressure (IUP) induced by electrical stimulation of the hypogastric nerve in anesthetized dogs with spontaneous BPH. All three drugs dose-dependently reduced both the increase in IUP and the mean blood pressure (MBP). The rank order of potencies was tamsulosin>silodosin>naftopidil for the reductions in both IUP and MBP. However, the uroselectivity (ED_ value for hypotensive effect/ID_ value for reduction in IUP) of silodosin (uroselectivity, 19.8) was about 21 and 4 times higher than that of tamsulosin (0.939) and naftopidil (4.94), respectively. These data suggest that silodosin might be one of the most useful medications for dysuria in BPH patients.
- 1 March 2006
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 126 (Special) , 225-230
Effect of Silodosin on Intraurethral Pressure Increase Induced by Hypogastric Nerve Stimulation in Dogs with Benign Prostatic Hyperplasia
We compared the urethral and cardiovascular effects of silodosin (selective α_-adrenoceptor antagonist), a novel medication for benign prostatic hyperplasia (BPH), with those of tamsulosin (selective α_/α_-adrenoceptor antagonist) and naftopidil (selective α_-adrenoceptor antagonist). We evaluated the effects of these three drugs on the increase in intraurethral pressure (IUP) induced by electrical stimulation of the hypogastric nerve in anesthetized dogs with spontaneous BPH. All three drugs dose-dependently reduced both the increase in IUP and the mean blood pressure (MBP). The rank order of potencies was tamsulosin>silodosin>naftopidil for the reductions in both IUP and MBP. However, the uroselectivity (ED_ value for hypotensive effect/ID_ value for reduction in IUP) of silodosin (uroselectivity, 19.8) was about 21 and 4 times higher than that of tamsulosin (0.939) and naftopidil (4.94), respectively. These data suggest that silodosin might be one of the most useful medications for dysuria in BPH patients.
- 1 January 2006
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 126 (Special_) , 225-230
Effect of Silodosin on Intraurethral Pressure Increase Induced by Hypogastric Nerve Stimulation in Dogs with Benign Prostatic Hyperplasia
We compared the urethral and cardiovascular effects of silodosin (selective α1A-adrenoceptor antagonist), a novel medication for benign prostatic hyperplasia (BPH), with those of tamsulosin (selective α1A/α1D-adrenoceptor antagonist) and naftopidil (selective α1D-adrenoceptor antagonist). We evaluated the effects of these three drugs on the increase in intraurethral pressure (IUP) induced by electrical stimulation of the hypogastric nerve in anesthetized dogs with spontaneous BPH. All three drugs dose-dependently reduced both the increase in IUP and the mean blood pressure (MBP). The rank order of potencies was tamsulosin>silodosin>naftopidil for the reductions in both IUP and MBP. However, the uroselectivity (ED15 value for hypotensive effect/ID50 value for reduction in IUP) of silodosin (uroselectivity, 19.8) was about 21 and 4 times higher than that of tamsulosin (0.939) and naftopidil (4.94), respectively. These data suggest that silodosin might be one of the most useful medications for dysuria in BPH patients.
- 1 January 2006
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 126 (Special_) , 225-230
Effect of Silodosin on Intraurethral Pressure Increase Induced by Hypogastric Nerve Stimulation in Dogs with Benign Prostatic Hyperplasia
We compared the urethral and cardiovascular effects of silodosin (selective α1A-adrenoceptor antagonist), a novel medication for benign prostatic hyperplasia (BPH), with those of tamsulosin (selective α1A/α1D-adrenoceptor antagonist) and naftopidil (selective α1D-adrenoceptor antagonist). We evaluated the effects of these three drugs on the increase in intraurethral pressure (IUP) induced by electrical stimulation of the hypogastric nerve in anesthetized dogs with spontaneous BPH. All three drugs dose-dependently reduced both the increase in IUP and the mean blood pressure (MBP). The rank order of potencies was tamsulosin>silodosin>naftopidil for the reductions in both IUP and MBP. However, the uroselectivity (ED15 value for hypotensive effect/ID50 value for reduction in IUP) of silodosin (uroselectivity, 19.8) was about 21 and 4 times higher than that of tamsulosin (0.939) and naftopidil (4.94), respectively. These data suggest that silodosin might be one of the most useful medications for dysuria in BPH patients.